Targovax to present at forthcoming conferences
(Thomson Reuters ONE) -
Oslo 31 May 2016 - Targovax, a clinical stage immuno-oncology company,
developing targeted immunotherapy treatments for cancer patients, announces that
members of its senior management team will participate in the following life
sciences and investor conferences:
Redeye Investor Forum
Stockholm, 1 June 2016
Participants: Magnus Jäderberg (CMO)
Presentation time: 18:00
Venue: Redeye HQ, Mäster Samuelsgatan 42, Stockholm
Redeye Investor Forum
Västerås, 7 June 2016
Participants: Magnus Jäderberg (CMO)
Presentation time: 19:30
Venue: Elite Stadshotellet, Stora Torget, Västerås
Småbolagsdagen 2016
Stockholm, 13 June 2016
Participants: Gunnar Gårdemyr (CEO)
Presentation time: 17:00 (Room 2 - Life Science)
Venue: Sheraton Stockholm Hotel, Tegelbackan 6, Stockholm
BIO International Convention
San Francisco, 6-9 June 2016
Participants: Gunnar Gårdemyr (CEO) and Peter Skorpil (VP Business Development)
The presentations will be available to download at www.targovax.com following
the event.
For further information, please contact:
Gunnar Gårdemyr, CEO
Phone: +46 73 083 77 79
Email: ggardemyr(at)targovax.com
Øystein Soug, CFO
Phone: +47 906 56 525
Email: oystein.soug(at)targovax.com
Arming the patient's immune system to fight cancer
Targovax is a clinical stage immuno-oncology company developing targeted
immunotherapy treatments for cancer patients. Targovax has a broad and
diversified immune therapy portfolio and aims to become a world leader in its
area. The company is currently developing two complementary and highly targeted
approaches in immuno-oncology.
ONCOS - 102 is a virus-based immunotherapy platform based on engineered
oncolytic viruses armed with potent immune-stimulating transgenes targeting
solid tumors. This treatment is designed to reactivate the immune system's
capacity to recognize and attack cancer cells.
TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the
difficult to treat RAS mutations found in more than 85% of pancreatic cancers,
50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards
demonstrating that TG vaccines will prolong time to cancer progression and
increase survival.
These product candidates will be developed in combination with multiple
treatments, including checkpoint inhibitors in several cancer indications.
Targovax also has a number of other cancer immune therapy candidates in the
early stages of development.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Targovax ASA via GlobeNewswire
[HUG#2016583]
Unternehmensinformation / Kurzprofil:
Datum: 31.05.2016 - 08:01 Uhr
Sprache: Deutsch
News-ID 474487
Anzahl Zeichen: 3357
contact information:
Town:
Lysaker
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 203 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Targovax to present at forthcoming conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
Targovax ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
